1.2 Medicare Pharmacy Coverage: Parts A, B, C, and D

1.2 Medicare Pharmacy Coverage: Parts A, B, C, and D

Medicare is the federal health insurance program established under Title XVIII of the Social Security Act of 1965. Administered by the Centers for Medicare & Medicaid Services (CMS) within the Department of Health and Human Services (HHS), Medicare provides coverage to individuals aged 65 and older, individuals under 65 with permanent disabilities who have received Social Security Disability Insurance (SSDI) for at least 24 months, and individuals of any age diagnosed with End-Stage Renal Disease (ESRD) requiring permanent dialysis or kidney transplant, or Amyotrophic Lateral Sclerosis (ALS).

+-----------------------------------------------------------------------------+
|                     THE FOUR PILLARS OF MEDICARE                            |
|                                                                             |
|  +------------------------+      +------------------------+                 |
|  |   MEDICARE PART A      |      |   MEDICARE PART B      |                 |
|  | Inpatient / Hospital   |      | Outpatient Medical /   |                 |
|  | Bundled DRG per-diem   |      | DME & Injected Drugs   |                 |
|  +------------------------+      +------------------------+                 |
|              \                                /                             |
|               \                              /                              |
|                v                            v                               |
|  +--------------------------------------------------------+                 |
|  |               MEDICARE PART C (MA / MA-PD)             |                 |
|  | Private Managed Care Plans replacing Original Medicare |                 |
|  +--------------------------------------------------------+                 |
|                                                                             |
|  +--------------------------------------------------------+                 |
|  |               MEDICARE PART D (PDP / MA-PD)            |                 |
|  | Standalone Outpatient Prescription Drug Benefit        |                 |
|  | 2026 IRA Redesign: $2,100 OOP Cap / No Donut Hole      |                 |
|  +--------------------------------------------------------+                 |
+-----------------------------------------------------------------------------+

---

1. Medicare Architecture: Parts A, B, C, and D

Understanding which Medicare component covers a specific drug or medical supply is essential to avoid claim rejections, billing audits, and improper out-of-pocket charges to vulnerable seniors.

Medicare Part A (Hospital Insurance)

• Covered Scope: Inpatient hospital care, short-term stays in skilled nursing facilities (SNFs) following a qualifying 3-day inpatient hospitalization (up to 100 days), home health care, and hospice care.
• Pharmacy Billing Mechanism: Medications administered during an inpatient hospital stay or covered SNF admission are bundled into the facility's prospective payment system (such as Diagnosis-Related Groups [DRGs] or Patient-Driven Payment Models [PDPM]). Pharmacies do not submit separate NCPDP or CMS-1500 claims for individual Part A oral tablets or IV bags; all pharmaceutical costs are included in the facility's daily per-diem reimbursement rate.

Medicare Part B (Medical Insurance)

Medicare Part B covers outpatient physician visits, diagnostic imaging, laboratory tests, outpatient hospital clinic visits, and a strictly defined scope of outpatient prescription drugs and Durable Medical Equipment (DME). Unlike Part D (which covers self-administered retail medications), Part B covers drugs tied to physician administration or medical equipment:

+-----------------------------------------------------------------------------+
|                 MEDICARE PART B PHARMACY BENEFIT SCOPE                      |
|                                                                             |
|  1. DME Inhalation Solutions: Albuterol, Ipratropium, Budesonide (for Neb) |
|  2. Diabetes Testing Supplies: Test strips, lancets, monitors, CGMs        |
|  3. Insulin Administered via Durable Infusion Pump (External Pump)         |
|  4. Immunosuppressants: Post-transplant (if Medicare covered the transplant)|
|  5. Oral Chemotherapy & Oral Antiemetics: Within 48 hours of chemotherapy   |
|  6. Part B Vaccines: Influenza, Pneumococcal, Hepatitis B (Risk), COVID-19  |
|  7. Physician-Administered Injectables: In-clinic chemo/biologics (Buy&Bill)|
+-----------------------------------------------------------------------------+

• Billing Parameters: Community and specialty pharmacies billing Part B items must enroll as Medicare Part B DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics, and Supplies) suppliers with the National Supplier Clearinghouse (NSC). Claims are submitted using standard HCPCS codes and ICD-10-CM diagnosis codes via electronic EDI 837P or real-time NCPDP transactions routed through Part B Durable Medical Equipment Medicare Administrative Contractors (DME MACs).
• Cost-Sharing: Standard Part B coverage requires an annual deductible ($257 in 2025, rising to $283 in 2026) followed by a 20% coinsurance of the Medicare-approved allowable amount, with no annual out-of-pocket cap under Original Medicare (unless the patient holds a Medicare Supplement / Medigap policy).

Medicare Part C (Medicare Advantage - MA / MA-PD)

• Managed Care Framework: Private commercial insurance companies (e.g., Humana, UnitedHealthcare, Aetna, Kaiser Permanente) approved by CMS offer Medicare Advantage plans that replace Original Medicare Part A and Part B. Members receive all inpatient, outpatient, and emergency services through the private insurer's managed care network (HMO or PPO structure).
• MA-PD Integration: When a Medicare Advantage plan incorporates prescription drug coverage, it is designated an MA-PD (Medicare Advantage Prescription Drug) plan. The beneficiary carries a single insurance card that unifies hospital, medical, and pharmacy benefits.

Medicare Part D (Prescription Drug Benefit)

• Outpatient Prescription Coverage: Enacted under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) and launched in 2006, Part D subsidizes outpatient self-administered prescription drugs delivered through private standalone Prescription Drug Plans (PDPs) or integrated MA-PD plans.
• Statutory Non-Covered Drug Categories: By federal law, certain medication classes are excluded from standard Part D coverage, including over-the-counter (OTC) medications, drugs for anorexia/weight loss/weight gain, fertility treatments, cosmetic hair growth, cough/cold symptomatic relief, prescription vitamins/minerals (except prenatal vitamins and fluoride preparations), and erectile dysfunction (ED) drugs (unless FDA-approved for a non-sexual indication like pulmonary arterial hypertension).

---

2. Medicare Part B vs. Part D Pharmacy Coverage Matrix

Distinguishing between Part B and Part D coverage represents one of the most heavily tested competency areas on the PTCB Billing & Reimbursement examination:

---

3. 2026 Inflation Reduction Act (IRA) Part D Benefit Redesign

The Inflation Reduction Act (IRA) of 2022 introduced the most extensive restructuring of the Medicare Part D prescription drug benefit since its inception. Effective for the 2026 plan year, the historic four-phase benefit model is replaced by a streamlined, highly protective three-phase structure.

+-----------------------------------------------------------------------------+
|                 HISTORICAL VS. 2026 IRA MEDICARE PART D STRUCTURE           |
|                                                                             |
|   HISTORICAL 4-PHASE MODEL (PRE-2025/2026)                                  |
|   [Deductible] ----> [Initial Coverage] ----> [COVERAGE GAP] ----> [Catastrophic]|
|   (100% Patient)     (25% Patient)            ("Donut Hole" 25%)   (5% Coinsurance)|
|                                                                             |
|   2026 IRA REDESIGNED 3-PHASE MODEL                                         |
|   [Phase 1: Deductible] ----------> [Phase 2: Initial Coverage] ----------> [Phase 3: Catastrophic]|
|   - 100% Patient OOP                - 25% Patient Cost-Sharing              - $0 PATIENT COPAY (0%) |
|   - Up to Statutory Max ($590-$615) - Until TrOOP Reaches $2,100 Cap (2026)        - 100% Plan/Mfr Funded  |
|                                                                             |
|   * PERMANENT ELIMINATION OF THE COVERAGE GAP ("DONUT HOLE")                |
|   * HARD ANNUAL TRUE OUT-OF-POCKET (TrOOP) CEILING: $2,100 IN 2026                   |
+-----------------------------------------------------------------------------+

Key IRA Reform Provisions for 2026

1. Hard Annual Out-of-Pocket Cap: $2,100 in 2026

Beginning in 2025, beneficiary annual out-of-pocket prescription liability was strictly capped at $2,000 True Out-of-Pocket (TrOOP); the cap is indexed annually and rises to $2,100 for the 2026 benefit year. Once a patient's cumulative spending on deductibles and standard copayments/coinsurance reaches the cap, they transition immediately into the Catastrophic Phase and pay $0 for all covered Part D medications for the remainder of the calendar year.

2. Permanent Elimination of the Coverage Gap ("Donut Hole")

The notorious Part D "coverage gap"—in which patients historically experienced a sudden surge in out-of-pocket costs after reaching the initial coverage limit—is permanently eradicated. Beneficiaries move directly from the Initial Coverage Phase to the Catastrophic Phase upon reaching the $2,100 TrOOP limit (2026).

3. $35 Monthly Insulin Copay Cap

Cost-sharing for all covered Part D insulin products (vials, disposable pens, cartridges) is legally capped at a maximum of $35 for a 30-day supply (and $70 for 60-day, $105 for 90-day supplies). This cap applies across all benefit phases, meaning the deductible does not apply to covered insulin.

4. $0 Cost-Sharing for ACIP-Recommended Vaccines

All adult vaccines recommended by the Advisory Committee on Immunization Practices (ACIP)—including Shingrix (herpes zoster), Arexvy / Abrysvo (RSV), and Boostrix / Adacel (Tdap)—are covered under Part D with $0 copay, $0 coinsurance, and no deductible, regardless of which benefit phase the patient occupies.

5. Manufacturer Discount Program (MDP)

To fund the expanded benefit and replace the former Coverage Gap Discount Program, the IRA established the Manufacturer Discount Program. Pharmaceutical manufacturers are mandated to provide a 10% discount on applicable brand-name drugs during the Initial Coverage Phase, and a 20% discount during the Catastrophic Phase, significantly shifting liability away from the Medicare trust fund.

+-----------------------------------------------------------------------------+
|              2026 PART D CATASTROPHIC PHASE LIABILITY BREAKDOWN             |
|                                                                             |
|   - Beneficiary Responsibility:     0%  ($0 Out-of-Pocket)                  |
|   - Part D Plan Sponsor Share:     60%  (Direct Insurer Liability)          |
|   - Manufacturer Discount (MDP):   20%  (Statutory Brand-Name Discount)     |
|   - Federal Government Reinsurance: 20%  (Down from historical 80%)         |
+-----------------------------------------------------------------------------+

---

4. Medicare Prescription Payment Plan (M3P / MPPP) / "Cost Smoothing"

Enacted under the Inflation Reduction Act and effective nationwide, the Medicare Prescription Payment Plan (M3P)—referred to in the PTCB exam content outline as Medication Prescription Payment Plans (MPPPs) and commonly known in pharmacy practice as "cost smoothing"—is a voluntary payment mechanism designed to prevent seniors from experiencing catastrophic upfront prescription costs at the start of a calendar year.

+-----------------------------------------------------------------------------+
|                  MEDICARE PRESCRIPTION PAYMENT PLAN (M3P)                   |
|                                                                             |
|   WITHOUT M3P (STANDARD POINT-OF-SALE):                                     |
|   - January Fill: High-Cost Specialty Drug ($1,500 allowed)                 |
|   - Patient pays $1,500 immediately at the pharmacy counter in January.     |
|                                                                             |
|   WITH M3P SMOOTHING (ELECTED ENROLLMENT):                                  |
|   - January Fill: Pharmacy counter charge is $0.                            |
|   - Part D Plan bills patient in 12 equal monthly installments ($125/mo).   |
|   - Maximum annual liability remains strictly bounded by the $2,100 OOP cap (2026).    |
+-----------------------------------------------------------------------------+

Operational Mechanisms of M3P

• Voluntary Election: Part D enrollees can opt into M3P before the plan year begins during Annual Open Enrollment, or at any point during the calendar year when filling an expensive medication.
• Zero Point-of-Sale Collection: When an enrolled M3P patient fills a prescription at the pharmacy counter, the NCPDP point-of-sale claim adjudicates with a $0 patient-pay amount. The pharmacy collects $0 from the beneficiary and receives full reimbursement directly from the Part D plan sponsor.
• Monthly Installment Billing: The Part D plan sponsor bills the enrollee directly on a monthly basis. The monthly payment calculation spreads the incurred out-of-pocket costs evenly over the remaining months of the calendar year according to a standardized CMS mathematical formula:

$\text{Monthly Installment} = \frac{\text{Total Remaining Unpaid Incurred Out-of-Pocket Costs}}{\text{Number of Remaining Months in Plan Year}}$